In the Czech Republic, the company has successfully transferred 470 plants to their outdoor greenhouse facility. MGC Pharmaceuticals has a partnership with the Czech Government’s Institute of Experimental Botany to cultivate cannabis for botanical and clinical research.
In Australia, the company is making progress in their partnership with the Royal Melbourne Institute of Technology to establish the Joint International Library of Cannabis Medicine. The library will contain a proprietary genetics database of cannabis strains as well as their medicinal indications. Additionally, MGC Pharma expects to submit its license application to begin cultivation in Australia in the coming weeks.
MGC Pharmaceuticals' Managing Director, Nativ Segev
"Our operations are progressing well within the Company's Botanic Division, with early signs of successful crops boding well for our research projects and our raw material production. We expect this season's crops to bring us further insights into how to enhance both our genetics and maximize our harvest, giving us a strong competitive advantage. "
Since the announcement Monday, shares of MGC Pharmaceuticals are up roughly 4%. Year to date, shares of MGC Pharmaceuticals are up more than 11%. This puts them in the middle performance wise versus their cannabis related peers on the ASX.
We're expanding our coverage of the marijuana industry in Australia as well as the European Union. To stay up to date, be sure to subscribe to our free Australian cannabis email newsletter and stay tuned for more coverage of the emerging marijuana industry in the European Union and surrounding countries. Also, don't forget to connect with The Daily Marijuana Observer on Facebook, Twitter and Instagram.
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.